Intensity Therapeutics, Inc. Common stock (INTS)

Intensity Therapeutics, Inc. Common stock (INTS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $11.9M; returns 1 day +1.9%, 1 week -3.0%, 1 year -46.1%.

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing cancer therapies. The company utilizes its DfuseRx technology to create drug formulations, that, upon direct injection, disperse throughout the tumor and diffuse therapeutic agents into cancer cells. This technology is designed to kill tumors and increase immune system recognition of cancers.

Groups INTS belongs to

• Biotechnology
• Recent Reverse Splits
• Oncology
• Clinical Stage Biotech
• Cancer Therapeutics
• Healthcare
• Pharmaceuticals
• Life Sciences
• Clinical Stage
• Immunotherapy

INTS financial model: income statement, cash flow and balance sheet